Ascendis Pharma A/S Stock News

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a report issued on Wednesday, BidAskClub reports. ASND has been the subject of a number o

Barclays PLC cut its position in Ascendis Pharma A/S (NASDAQ:ASND) by 95.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 378 share

Analysts forecast that Ascendis Pharma A/S (NASDAQ:ASND) will announce earnings per share (EPS) of ($1.29) for the current quarter, according to Zacks. Three analysts have issued estimates for Ascendi

Oppenheimer initiated coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a report released on Thursday morning, BenzingaRatingsTable reports. The firm issued an outperform rating and a $199.00

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P; 500 Index wa

Citigroup Inc. grew its position in Ascendis Pharma A/S (NASDAQ:ASND) by 196.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (

Banco Bilbao Vizcaya Argentaria S.A. purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) during the fourth quarter, according to its most recent disclosure with the Securities & Excha

Equities research analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to announce sales of $2.26 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates fo

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Ascendis Pharma (ASND) has seen solid estimate revision activity over the past month, and belongs to a strong industry as well.

Ascendis Pharma (ASND) has seen solid estimate revision activity over the past month, and belongs to a strong industry as well.

Ascendis Pharma (NASDAQ:ASND) initiated with Outperform rating with a $199 (97% upside) price target at Oppenheimer.Livongo Health (NASDAQ:LVGO) initiated with Buy rating and $30 (39% upside) price ta